Accumulating evidence has demonstrated that cancer stem cells (CSCs) are responsible for tumor initiation and progression. CSCs contribute to therapeutic resistance and are considered to be the most likely cause of cancer relapse.1, 2 and 3 Consequently, much effort has been made to design molecules that can target CSCs specifically and sensitize them to therapy.4